Search Result

Results for "

pain-related diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Autophagy (2) COX (3) Drug Derivative (3) Drug Intermediate (1) Drug Metabolite (2) Isotope-Labeled Compounds (1) Opioid Receptor (2) Reference Standards (3) Sodium Channel (4)
By Research Areas:	Cancer (2) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (8) Neurological Disease (13)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Interleukin Related Oxysterol-binding Protein-related Protein (ORP) Mas-related G-protein-coupled Receptor (MRGPR) Trk Receptor ROR NEKs Kallikrein Atg4 CGRP Receptor RUNX Atg8/LC3 Arp2/3 Complex ATM/ATR sFRP-1 CD44 Neuropeptide S Receptor Cdc42-binding kinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-Z7640

4-Desmethyl-2-methyl celecoxib	COX	Inflammation/Immunology
4-Desmethyl-2-methyl celecoxib (Compound 1g) is an orally active and selective Cyclooxygenase-2 (COX-2) inhibitor with an IC₅₀ value of 0.069 μM. 4-Desmethyl-2-methyl celecoxib shows anti-inflammatory, analgesic, and antipyretic activities. 4-Desmethyl-2-methyl celecoxib can reduces the synthesis of prostaglandins. 4-Desmethyl-2-methyl celecoxib is promising for research of inflammatory diseases and pain-related diseases, such as rheumatoid arthritis and osteoarthritis .

HY-155635

Nav1.8-IN-4	Sodium Channel	Infection
Nav1.8-IN-4 (compound 9a) is a Nav1.8 channel inhibitor (IC₅₀=0.014 μM). Nav1.8-IN-4 can be used for research on pain-related diseases .

HY-W050088

Isoxepac HP 549	Drug Derivative	Neurological Disease Inflammation/Immunology
Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .

HY-N0451

Acacetin 10+ Cited Publications 5,7-Dihydroxy-4'-methoxyflavone	Apoptosis Autophagy	Neurological Disease Inflammation/Immunology Cancer
Acacetin (5,7-Dihydroxy-4'-methoxyflavone) is an orally active flavonoid derived from Dendranthema morifolium. Acacetin docks in the ATP binding pocket of PI3Kγ. Acacetin causes cell cycle arrest and induces apoptosis and autophagy in cancer cells. Acacetin has potent anti-cancer and anti-inflammatory activity and has the potential for pain-related diseases research .

HY-114235

SCP-1	Drug Intermediate	Neurological Disease
SCP-1 (Compound C-1) is the key intermediate for synthesizing the non-opioid analgesic drug SRP-3D (DA). SCP-1 can be used for the research of neurological disease, such as pain-related diseases .

HY-160593

Nav1.8-IN-12	Sodium Channel	Neurological Disease
Nav1.8-IN-12 (Compound 23 R) is a Nav1.8 channel inhibitor. Nav1.8-IN-12 can be used in the study of pain-related diseases .

HY-158979

Nav1.8-IN-14	Sodium Channel	Neurological Disease
Nav1.8-IN-14 (compound 20) is a potent and selective Nav1.8 inhibitor. Nav1.8-IN-14 can be used in the study of pain-related diseases .

HY-162246

Nav1.8-IN-5	Sodium Channel	Cardiovascular Disease Neurological Disease
Nav1.8-IN-5 (Example 1) is a voltage-gated sodium channel Nav1.8 inhibitor. Nav1.8-IN-5 can be used for Nav1.8-mediated diseases, such as pain and pain-related disorders, as well as cardiovascular diseases (such as atrial fibrillation) research .

HY-N0451R

Acacetin (Standard) 5,7-Dihydroxy-4'-methoxyflavone (Standard)	Reference Standards Apoptosis Autophagy	Neurological Disease Inflammation/Immunology Cancer
Acacetin (Standard) is the analytical standard of Acacetin. This product is intended for research and analytical applications. Acacetin (5,7-Dihydroxy-4'-methoxyflavone) is an orally active flavonoid derived from Dendranthema morifolium. Acacetin docks in the ATP binding pocket of PI3Kγ. Acacetin causes cell cycle arrest and induces apoptosis and autophagy in cancer cells. Acacetin has potent anti-cancer and anti-inflammatory activity and has the potential for pain-related diseases research .

HY-W050088S

Isoxepac-d6 HP 549-d₆	Isotope-Labeled Compounds Drug Derivative	Neurological Disease Inflammation/Immunology
Isoxepac-d₆ (HP 549-d₆) is the deuterium labeled Isoxepac (HY-W050088). Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .

HY-W050088R

Isoxepac (Standard) HP 549 (Standard)	Reference Standards Drug Derivative	Neurological Disease Inflammation/Immunology
Isoxepac (Standard) (HP 549 (Standard)) is the analytical standard of Isoxepac (HY-W050088). This product is intended for research and analytical applications. Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .

HY-B2121

6-Methoxy-2-naphthoic acid 6-MNA; Naproxen impurity O	Drug Metabolite COX	Neurological Disease Inflammation/Immunology
6-Methoxy-2-naphthoic acid (6-MNA) is the active metabolite of Nabumetone (HY-B0559). 6-Methoxy-2-naphthoic acid is also an inhibitor of COX-1 and COX-2. 6-Methoxy-2-naphthoic acid can inhibit the synthesis of gastric mucosal prostaglandin E₂. 6-Methoxy-2-naphthoic acid can be used in the research of inflammation and pain-related diseases. In addition, 6-Methoxy-2-naphthoic acid is an impurity in Naproxen (HY-15030) and can also be used in the synthesis of other active compounds .

HY-142918

μ opioid receptor agonist 1	Opioid Receptor	Neurological Disease
μ opioid receptor agonist 1 （Compound H-1a）is an optically pure oxaspiro ring substituted pyrrolopyrazole derivative, acts as a MOR receptor agonist and can be used for the research of pain and pain related diseases .

HY-142919

μ opioid receptor agonist 2	Opioid Receptor	Neurological Disease
μ opioid receptor agonist 2 （Compound H-3）is an optically pure oxaspiro ring substituted pyrrolopyrazole derivative, acts as a MOR receptor agonist and can be used for the research of pain and pain related diseases .

HY-B2121R

6-Methoxy-2-naphthoic acid (Standard) 6-MNA (Standard); Naproxen impurity O (Standard)	Reference Standards Drug Metabolite COX	Neurological Disease Inflammation/Immunology
6-Methoxy-2-naphthoic acid (Standard) (6-MNA (Standard)) is the analytical standard of 6-Methoxy-2-naphthoic acid (HY-B2121). This product is intended for research and analytical applications. 6-Methoxy-2-naphthoic acid (6-MNA) is the active metabolite of Nabumetone (HY-B0559). 6-Methoxy-2-naphthoic acid is also an inhibitor of COX-1 and COX-2. 6-Methoxy-2-naphthoic acid can inhibit the synthesis of gastric mucosal prostaglandin E₂. 6-Methoxy-2-naphthoic acid can be used in the research of inflammation and pain-related diseases. In addition, 6-Methoxy-2-naphthoic acid is an impurity in Naproxen (HY-15030) and can also be used in the synthesis of other active compounds.

Cat. No.	Product Name

HY-L139

Pain-Related Compound Library	2,806 compounds
Pain is a kind of distressing feeling caused by the stimulation of tissue damage. According to the International Association for the Study of Pain (IASP), pain is defined as ”An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”. Pain is usually classified according to its location, duration, underlying causes, and intensity. For example, acute and chronic pain, muscle pain, and nerve pain. Pain is the main symptom of most diseases, which seriously affects the quality of life and body function of patients. In the medical treatment of pain, anti-inflammatory drugs and opioid analgesic agents have traditionally been used, but the side effects are serious. In recent years, targeted drugs targeting the ERK/MAPK pathway or other targets have gradually become a research hotspot. MCE supplies a unique collection of 2,806 compounds targeting key proteins in the pain system. MCE Pain-Related Compound Library is a useful tool for pain related research and anti-pain drug development.

Pain-Related Compound Library

2,806 compounds

Pain is a kind of distressing feeling caused by the stimulation of tissue damage. According to the International Association for the Study of Pain (IASP), pain is defined as ”An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”.

Pain is usually classified according to its location, duration, underlying causes, and intensity. For example, acute and chronic pain, muscle pain, and nerve pain. Pain is the main symptom of most diseases, which seriously affects the quality of life and body function of patients. In the medical treatment of pain, anti-inflammatory drugs and opioid analgesic agents have traditionally been used, but the side effects are serious. In recent years, targeted drugs targeting the ERK/MAPK pathway or other targets have gradually become a research hotspot.

MCE supplies a unique collection of 2,806 compounds targeting key proteins in the pain system. MCE Pain-Related Compound Library is a useful tool for pain related research and anti-pain drug development.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0451

Acacetin 10+ Cited Publications 5,7-Dihydroxy-4'-methoxyflavone	Neurological Disease Classification of Application Fields Flavones Anti-aging Source classification Dendranthema morifolium (Ramat.) Tzvel. Plants Compositae Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Phenols Polyphenols Inflammation/Immunology Disease Research Fields	Apoptosis Autophagy
Acacetin (5,7-Dihydroxy-4'-methoxyflavone) is an orally active flavonoid derived from Dendranthema morifolium. Acacetin docks in the ATP binding pocket of PI3Kγ. Acacetin causes cell cycle arrest and induces apoptosis and autophagy in cancer cells. Acacetin has potent anti-cancer and anti-inflammatory activity and has the potential for pain-related diseases research .

HY-N0451R

Acacetin (Standard) 5,7-Dihydroxy-4'-methoxyflavone (Standard)	Neurological Disease Classification of Application Fields Anti-aging Source classification Dendranthema morifolium (Ramat.) Tzvel. Plants Compositae Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Phenols Inflammation/Immunology Disease Research Fields	Reference Standards Apoptosis Autophagy
Acacetin (Standard) is the analytical standard of Acacetin. This product is intended for research and analytical applications. Acacetin (5,7-Dihydroxy-4'-methoxyflavone) is an orally active flavonoid derived from Dendranthema morifolium. Acacetin docks in the ATP binding pocket of PI3Kγ. Acacetin causes cell cycle arrest and induces apoptosis and autophagy in cancer cells. Acacetin has potent anti-cancer and anti-inflammatory activity and has the potential for pain-related diseases research .

Cat. No.	Product Name	Chemical Structure

HY-W050088S

Isoxepac-d6
Isoxepac-d₆ (HP 549-d₆) is the deuterium labeled Isoxepac (HY-W050088). Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .

Isoxepac-d6

Isoxepac-d₆ (HP 549-d₆) is the deuterium labeled Isoxepac (HY-W050088). Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks